Bone Biologics Corp. - BBLG Net earnings per one share for the last twelve months

Bone Biologics specializes in developing innovative proteins for bone regeneration in traumatology. The GURU.Markets platform displays a chart of the YoY ttm earnings per share trend, where 92.60 indicates the level of this metric. Bone Biologics is implementing environmental ESG standards into its production, while its patent protection strategy ensures unique clinical value for its products, eliminating the impact of price wars.
Bone Biologics Corp. - analytical breakdowns and key metrics (BBLG)

Developing proprietary bone grafts requires colossal FDA certification costs. These expenses directly impact net income, as measured by the rolling annual EPS YoY trend. This metric calculates the percentage change in earnings per share over the last 12 months, revealing the actual efficiency of the business. It is critical for investors to distinguish random spikes from sustainable yield growth. Analyzing this curve allows for an assessment of the fundamental stability of Bone Biologics (BBLG).